Han Xiaoying, Meng Min, Zhang Tiehong, Wang Jiao, Huang Guanghui, Ni Yang, Li Wenhong, Dai Jianjian, Yang Xia, Ye Xin
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong Province, China.
J Cancer Res Ther. 2022 Sep;18(5):1440-1443. doi: 10.4103/jcrt.jcrt_831_21.
The programmed cell death 1 (PD-1) inhibitor - camrelizumab - is a promising agent for the treatment of several malignancies. Secondary hypophysitis has been reported in patients treated with the other PD-1 inhibitors such as nivolumab and pembrolizumab. However, camrelizumab-related hypophysitis has not yet been described. Herein, we report three cases of hypophysitis secondary to camrelizumab therapy. Case 1 was a 60-year-old male patient with non-small-cell lung carcinoma, who was diagnosed with central adrenal insufficiency associated with hypophysitis after 11 cycles of camrelizumab treatment (200 mg every 2 weeks). Glucocorticoid therapy rapidly improved his symptoms. Case 2 was a 68-year-old male patient with hepatocellular carcinoma who received ten cycles of camrelizumab (200 mg every 2 weeks) plus apatinib (250 mg daily), before the diagnosis of hypophysitis. Steroid therapy was also efficacious. Case 3 was a 69-year-old male patient diagnosed with renal carcinoma. After eight cycles of camrelizumab therapy (200 mg every 2 weeks) combined with oral apatinib (250 mg daily), the patient presented with hypophysitis, which responded well to glucocorticoid therapy. These results suggest a caution for hypophysitis in patients treated with camrelizumab.
程序性细胞死亡蛋白1（PD-1）抑制剂——卡瑞利珠单抗——是一种有前景的治疗多种恶性肿瘤的药物。在接受纳武利尤单抗和帕博利珠单抗等其他PD-1抑制剂治疗的患者中，曾有继发性垂体炎的报道。然而，卡瑞利珠单抗相关的垂体炎尚未见描述。在此，我们报告3例卡瑞利珠单抗治疗继发垂体炎的病例。病例1是一名60岁的非小细胞肺癌男性患者，在接受11个周期的卡瑞利珠单抗治疗（每2周200mg）后，被诊断为与垂体炎相关的中枢性肾上腺功能不全。糖皮质激素治疗迅速改善了他的症状。病例2是一名68岁的肝细胞癌男性患者，在诊断垂体炎之前接受了10个周期的卡瑞利珠单抗（每2周200mg）加阿帕替尼（每日250mg）治疗。类固醇治疗也有效。病例3是一名69岁被诊断为肾癌的男性患者。在接受8个周期的卡瑞利珠单抗治疗（每2周200mg）联合口服阿帕替尼（每日250mg）后，该患者出现垂体炎，对糖皮质激素治疗反应良好。这些结果提示在接受卡瑞利珠单抗治疗的患者中应警惕垂体炎。
